{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Hepion Pharmaceuticals, Inc.
Is Hepion Pharmaceuticals, Inc. technically bullish or bearish?
As of March 18, 2025, Hepion Pharmaceuticals shows a mildly bearish trend, with daily moving averages indicating bearish conditions, while weekly MACD and KST suggest mild bullishness, resulting in mixed signals and a lack of strong momentum.
Who are in the management team of Hepion Pharmaceuticals, Inc.?
As of March 2022, the management team of Hepion Pharmaceuticals, Inc. includes Dr. Gary Jacob (Chairman), Dr. Robert Foster (CEO and Chief Scientific Officer), and several independent directors: Dr. Thomas Adams, Dr. Timothy Block, Mr. John Brancaccio, Dr. Arnold Lippa, and Dr. Peter Wijngaard. This team provides governance and strategic direction for the company.
What does Hepion Pharmaceuticals, Inc. do?
Hepion Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. It operates as a micro-cap company with a market cap of $0.89 million and reported a net profit loss of $6 million as of March 2025.
How big is Hepion Pharmaceuticals, Inc.?
As of Jun 18, Hepion Pharmaceuticals, Inc. has a market capitalization of 0.89 million, with net sales of 0.00 million and a consolidated net profit of -16.46 million. Shareholder's funds were reported at -1.86 million, and total assets stood at 1.61 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
